Mersana Therapeutics, Inc. announced that after a strategic evaluation the Company will prioritize its resources to focus on the advancement of XMT-1536, a first-in-class ADC candidate targeting NaPi2b. As a result, Mersana and its partner, Takeda, plan to terminate the co-development collaboration for XMT-1522. Mersana will work with investigators to ensure that patients benefitting from XMT-1522 will continue to have access to the therapy as needed.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.16 USD | +3.85% |
|
+12.30% | -7.54% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.54% | 255M | |
+20.32% | 127B | |
+24.62% | 117B | |
+25.44% | 27.67B | |
-17.71% | 20.33B | |
-15.17% | 16.79B | |
-15.11% | 15.63B | |
+12.48% | 14.84B | |
-47.10% | 14.65B | |
+56.15% | 14.43B |
- Stock Market
- Equities
- MRSN Stock
- News Mersana Therapeutics, Inc.
- Mersana Therapeutics, Inc. and Takeda Plan to Terminate the Co-Development Collaboration for XMT-1522